Due to advances in detection and treatment of cancer, especially the rise in the targeted therapy, the five-year relative survival rate of all cancers has increased significantly. However, according to the analysis of the survival rate of cancer patients in 2019, the survival rate of most cancers is still less than five years. Therefore, to combat complex cancer and further improve the 5-year survival rate of cancer patients, it is necessary to develop some new anticancer drugs. Because of the adaptive evolution of toxic species for millions of years, the venom sac is a "treasure bank", which has millions of biomolecules with high affinity and stability awaiting further development. Complete utilization of venom-based and bacteria-derived drugs in the market is still staggering because of incomplete understanding regarding their mode of action. In this review, we focused on the currently identified targets for anticancer effects based on venomous and bacterial biomolecules, such as ion channels, membrane non-receptor molecules, integrins, and other related target molecules. This review will serve as the key for exploring the molecular mechanisms behind the anticancer potential of venom-based and bacteria-derived drugs and will also lay the path for the development of anticancer targeted therapy.

由于癌症检测和治疗的进步，特别是靶向治疗的兴起，所有癌症的五年相对生存率显着提高。但根据2019年癌症患者生存率分析，大部分癌症患者的生存率仍不足5年。因此，为了对抗复杂癌症，进一步提高癌症患者的5年生存率，有必要开发一些新的抗癌药物。由于有毒物种数百万年的适应性进化，毒囊是一座“宝库”，拥有数以百万计的具有高亲和力和稳定性的生物分子等待进一步开发。由于对其作用方式的不完全了解，市场上对毒液和细菌衍生药物的完全利用仍然令人震惊。在这篇综述中，我们重点关注了目前基于毒液和细菌生物分子（如离子通道、膜非受体分子、整合素和其他相关靶分子）确定的抗癌作用靶点。该综述将成为探索毒液和细菌衍生药物抗癌潜力背后的分子机制的关键，也将为抗癌靶向治疗的发展铺平道路。和其他相关的靶分子。该综述将成为探索毒液和细菌衍生药物抗癌潜力背后的分子机制的关键，也将为抗癌靶向治疗的发展铺平道路。和其他相关的靶分子。该综述将成为探索毒液和细菌衍生药物抗癌潜力背后的分子机制的关键，也将为抗癌靶向治疗的发展铺平道路。